In February, the AASM received a request from UnitedHealthcare to comment on a proposed coverage strategy for zolpidem sublingual tablets (Intermezzo).  The AASM Executive Committee carefully considered the UnitedHealthcare proposal and submitted comments in March.  After considering the AASM’s comment letter, UnitedHealthcare has made the decision to continue to exclude Intermezzo from their Pharmacy Benefit.  For more detailed information on UnitedHealthcare’s decision, see their written response to the AASM